Willow Biosciences

SUNNYVALE, Calif. , March 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredients is pleased to announce its financial and operating results for the three months and year ended December 31, 2024, and an update in respect of the disposition of Company's operating subsidiary (as announced via press release on March 14, 2025).» Mehr auf prnewswire.com

SUNNYVALE, Calif. , Jan. 20, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has initiated a formal strategic review process to identify, assess and evaluate a broad range of potential strategic alternatives.» Mehr auf prnewswire.com

Company reports record revenue of $1.7 million in Q3 Company announced a partnership in the high growth biopesticides sector that is expected to generate over $2 million in revenue in its first year Company closed a brokered financing for aggregate gross proceeds of $1.6 million Company signed a royalty agreement with Kalsec that includes milestone payments and tiered royalty payments on net worldwide sales after launch Company signed a second program with a global ingredient manufacturer to develop an enzyme for a large volume API and in November successfully completed its first program with the partner Willow increasing its 2024 revenue guidance for the year to over $4.5 million SUNNYVALE, Calif. , Nov. 12, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces third quarter financial results and provides a corporate update.» Mehr auf prnewswire.com